Market Newsdesk

FORT LEE, NJ, Dec. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Clikia Corp. (OTC:CLKA) (“Clikia” or the “Company”), an emerging leader in the global custom luxury goods marketplace, is pleased to announce that the Company’s projected year-end topline performance is expected to exceed $3.5 million in total revenues.

“2020 has been a tough year for everyone, but we managed to exceed our objectives and we feel confident we will see accelerating growth in 2021 provided we have the resources in place to make key investments,” commented Anil Idnani, CEO of Clikia. “At this point, we are clearly on pace to dramatically outperform our $2 million topline objective for the year, perhaps nearly doubling it. And we look forward to a big year ahead.”

The Company continues to build new relationships and management continues to see further growth ahead. As Clikia broadens its capital base, the Company feels confident that it will be able to scale up through a combination of advantageous inventory construction and a multi-pronged approach to a strong relationship with end-market consumers in the high-end, custom luxury goods marketplace.

About Clikia Corp

Clikia Corp. was incorporated in 2002 in the State of Nevada, under the name MK Automotive, Inc. Our corporate name changed to Clikia Corp. in July 2017. In April 2020, our company experienced a change in control, pursuant to which Mr. Anil Idnani became our controlling shareholder and sole officer and director. Following such change-in-control transaction, in May 2020, we acquired all of the assets, including the going business, of Maison Luxe, LLC, a Delaware limited liability. Our wholly owned subsidiary, Maison Luxe, Inc., a Wyoming corporation, now owns the acquired assets and operates the acquired business of Maison Luxe, LLC. Currently, this constitutes the entirety of our company’s business operations. Our company’s newly elected sole officer and director, Mr. Anil Idnani, founded the recently acquired Maison Luxe business with the vision of offering highly desired luxury retail consumer items that are responsibly sourced and affordable to the end customer. Because of the dynamics and structure with the luxury retail industry, customers who desire luxury items are unable to avail themselves of such items, due to the unreliable nature of sellers and exorbitant prices. It is this void in the marketplace that Mr. Idnani identified as a business opportunity and established Maison Luxe to provide customers with the experience of purchasing luxury items as a standard. The business known as “Maison Luxe” was founded in January 2020, with the vision of becoming an industry leader in luxury retail. MaisonLuxe focuses its efforts primarily within the fine timepieces and jewelry segments both on a wholesale and B2C (business-to-consumer) basis. The Company now also owns its Amani Jewelers subsidiary, which operates in the jewelry marketplace, with a strategic focus on the rapidly growing lab-grown diamonds market.

For more information please reference https://www.maisonluxeny.com/investors

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others. such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. 

Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report. 

Corporate Contact:

www.maisonluxeny.com
551-486-3980
[email protected]

• Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy
  
  
• EC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on existing medications, including stiripentol
• First EU market launch planned for Germany in Q1 2021
  

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) — Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA^® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Dravet syndrome is a rare, lifelong epilepsy that begins in infancy and is marked by severe refractory seizures, frequent medical emergencies, significant cognitive and behavioral impairments, and an increased risk of sudden premature death (SUDEP).

“We deeply appreciate the physicians and Dravet community whose support led to this important milestone,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “With the EC approval in place, we can now begin making FINTEPLA more widely available for the treatment of Dravet syndrome patients in Europe who seek new safe and effective treatment options.”

The EC’s approval of FINTEPLA was based on positive safety and efficacy results from two randomized, international, multi-center, placebo-controlled Phase 3 trials (Study 1 and Study 2), as well as data from an interim analysis of a long-term, open-label extension study in 330 Dravet syndrome patients treated up to 3 years.

“After a healthy start in life, children with Dravet syndrome suffer from frequent and prolonged epileptic seizures, which determine the future of the child and mean that parents are on constant alert. Current treatments for Dravet syndrome are unsatisfactory, resulting in the disease affecting motor and mental development,” said Dr. Tilman Polster, a pediatric epilepsy specialist at the Mara Hospital of the Bethel Epilepsy Centre in Bielefeld, Germany, and primary investigator for fenfluramine oral solution in Dravet syndrome in Germany. “Experience from clinical studies has shown that FINTEPLA offers an impressive reduction in seizures, plus an improvement in quality of life. In conjunction with the ongoing data being collected on the safety profile of the therapy, FINTEPLA represents an effective new treatment option and an important hope for the families concerned.”

When added to other antiepileptic therapies, including stiripentol, FINTEPLA provided a highly statistically significant and clinically meaningful reduction in convulsive seizure frequency. The most commonly reported adverse events that occurred in patients treated with this included decreased appetite, diarrhea, pyrexia, fatigue, upper respiratory tract infection, lethargy, somnolence and bronchitis.

With this approval, and subject to price and reimbursement being implemented according to national regulations, Zogenix will be able to market FINTEPLA in all European Union member countries, and in the United Kingdom, Norway, Iceland, and Liechtenstein.

Controlled Access Program

FINTEPLA will be available in Europe under a controlled access program requested by the European Medicines Agency to prevent off-label use for weight management and to confirm that prescribing physicians have been informed of the need for periodic cardiac monitoring in patients taking FINTEPLA.

Zogenix will also conduct the FINTEPLA Registry, an observational registry to provide data on long-term safety of FINTEPLA and frequency of echocardiographic monitoring in routine practice.

Earlier this year, FINTEPLA was approved by the U.S. Food & Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome in patients aged two years and older. In addition, Zogenix recently reported positive results of a third Phase 3 study of FINTEPLA in Dravet syndrome to support planned registration in Japan, which corroborated the highly statistically significant and clinically meaningful convulsive seizure reductions seen in earlier multinational Phase 3 studies. FINTEPLA is also being studied for the potential treatment of seizures associated with other rare epilepsies.

About Dravet Syndrome

Dravet syndrome is a rare, devastating and life-long form of epilepsy that generally begins in infancy and is marked by frequent, treatment-resistant seizures, significant developmental, motor, and behavioral impairments, and an increased risk of sudden unexpected death in epilepsy (SUDEP). Affecting one in 15,700 live births in the U.S. and approximately one in 20,000 to 40,000 live births in Europe, most patients follow a course of developmental delay with cognitive, motor and behavioral deficits that persist into adulthood. Dravet syndrome severely impacts quality of life for patients, families and caregivers due to the high physical, emotional, caregiving, and financial burden associated with the disease.

About Zogenix

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA^® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency (being developed through its subsidiary Modis Therapeutics). Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for genetic rare epilepsies.

Forward-Looking Statement

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed,” and similar expressions are intended to identify forward-looking statements. These statements include the potential that fenfluramine oral solution will be an important new treatment option for Dravet syndrome patients; Zogenix’s plans to commercialize fenfluramine in Europe, including the timing of the launch. These statements are based on Zogenix’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix’s business, including, without limitation: Zogenix’s ability to successfully launch FINTEPLA, including launching a controlled access program implemented due to risks related to valvular heart disease and pulmonary arterial hypertension, and the conduct of the FINTEPLA Registry, and the timing thereof; the COVID-19 pandemic may disrupt Zogenix’s business operations, impairing the ability to commercialize FINTEPLA in Europe and Zogenix’s ability to generate product revenue in Europe; Zogenix may not be successful in executing its sales and marketing strategy for the commercialization of FINTEPLA in Europe; unexpected adverse side effects or inadequate therapeutic efficacy of fenfluramine that could limit commercialization, or that could result in recalls or product liability claims; and other risks described in Zogenix’s prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACTS:

Zogenix

Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | [email protected]

Investors

Brian Ritchie 
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | [email protected]

Media


In Europe

: Kerry Lloyd-Jones, Account Director, Porter Novelli
+44 (0) 7949 794 290 | [email protected]
In the US: Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | [email protected]

 

SYDNEY, Australia, Dec. 21, 2020 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs.

Topical Phase I/II Human Clinical Trial Submission

Topical Phase I/II human clinical study is on track and progressing well. The Company recently announced it has received Human Research Ethics Approval for its Phase I/II human topical clinical trial in infected burn wounds and is closely working with South Metropolitan Health Service (Department of WA Health) on operational specifics with first patient treatment anticipated Q1 2021.

Intravenous Phase I Human Clinical Trial

Phase I clinical trial is progressing well with onsite audits this week and patient screening expected to take place in Q1 of 2021. The Company’s lead product RECCE^® 327 (R327) has been dispatched to clinical research facility CMAX in Adelaide, who have 30,000 registered patient volunteers on file.

Murdoch Children’s Research Institute

Independent animal ethics commitee has approved the first preclinical animal studies to assess potential of RECCE^® 435 (R435) administered orally for the treatment of Helicobacter pylori (H. pylori) gastric infection, at Murdoch Children’s Research Institute (MCRI). Samples of R435 have been received by MCRI, and the work being led by world H. pylori expert Professor Phil Sutton, Head of Mucosal Immunology at MCRI,, is on track for first data to be reported in Q1 2021.

SARS-CoV-2 (COVID-19) Studies

During the current quarter, the Company received encouraging results from SARS-CoV-2 studies in both Australia and the United States, with each advancing to their respective next stages. In the United States, both R327 and RECCE^® 529 (R529) compounds are in advanced stages of in vivo testing completion according to international COVID-19 study 1 protocols in leading testing species of hamsters and ferrets.¹ The two gold-standard studies in COVID-19 testing allows for the assessment of various modes of administration to combat the disease.

The first of the hamster data via intranasal administration is expected within the next two weeks, with ferret animal data via other modes of administration expected to follow soon after.

Looking ahead

The Company’s continues to manage a strong balance sheet in excess of $23 million AUD (ex anticipated R&D in-flow) in support of its infectious disease activities and looks forward to updating investors over the time ahead.

¹ https://www.nature.com/articles/s41586-020-2787-6

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE^® 327 and RECCE^® 435, and RECCE^® 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE^® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new antibiotic compound, RECCE^® 435, has been formulated for oral use.

The FDA has awarded RECCE^® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE^® technologies targeting synergistic, unmet medical needs.

Corporate Contact

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 8075 4585
[email protected]

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
[email protected]

Media and Investor Relations (USA)

Meredith Sosulski, Ph.D.
LifeSci Communications
+1 929 469 3851
[email protected]

LAFAYETTE, La., Dec. 21, 2020 (GLOBE NEWSWIRE) — Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced it has acquired a 5% interest in VeruStat, Inc, a newly created company focusing on remote patient monitoring (“RPM”), for approximately $600,000 using cash on hand.

The investment is part of the Company’s launch into the healthcare technology sector, and will immediately allow the Company’s salesforce to offer a new revenue source to its physician network around the country. RPM platforms allow physicians to bill for safely monitoring patients inside of the home that are struggling with chronic diseases. The VeruStat RPM solution will be placed in the home in conjunction with Viemed’s existing patient engagement platform (“PEP”). Preliminary data indicates that the use of Viemed’s internally developed PEP results in better patient compliance along with labor and workflow efficiencies. The Company is currently expanding the number of patients utilizing the PEP technology.

“The pandemic has revealed a great demand by physicians and patients to safely use technology to provide patient care inside of the home,” said Casey Hoyt, Viemed CEO. “We are excited to be partnering with VeruStat in the RPM space, as their unique solution will fit well with our physician network. While the RPM space is new, it complements our mission of interacting more frequently with chronically ill patients across multiple disease states, even beyond respiratory illnesses. We fully expect the RPM platform to add incremental revenue in 2021 on a standalone basis, while driving new adjacencies and adding to our core respiratory business.”

ABOUT VIEMED HEALTHCARE, INC.

Viemed, through its indirect wholly-owned subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered, L.L.C., is a home medical equipment supplier that provides post-acute respiratory care services in the United States. Sleep Management, L.L.C. focuses on disease management and improving the quality of life for respiratory patients through clinical excellence, education, and technology. Its service offerings are based on effective home treatment with respiratory care practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Home Sleep Delivered, L.L.C. focuses on providing in-home sleep testing for sleep apnea sufferers. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
[email protected]

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
[email protected]

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s expectations regarding the performance of the remote patient monitoring aspect of its business, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company’s patient base and revenues, employees, and equipment and supplies; the Company may be subject to significant capital requirements and operating risks; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of shares in the capital of the Company; the Company’s novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the impact of the previously disclosed restatement and correction of the Company’s previously issued financial statements; the previously disclosed identified material weakness in the Company’s internal control over financial reporting and the Company’s ability to remediate that material weakness; the initiation of legal or regulatory proceedings with respect to the restatement and corrections; the adverse effects on the Company’s business, results of operations, financial condition and stock price, as a result of the restatement and correction process; the Company’s status as an emerging growth company and a foreign private issuer; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the recent COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

PRESS RELEASE

December 21, 2020

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the further expansion of its executive team with the appointments of Denelle Waynick as Chief Legal Officer and Kyle
Haraldsen as Chief Technical Operations Officer. The positions will be based in the U.S. and will support Saniona’s advancement of clinical trials for Tesomet and SAN711 as well as the company’s growing U.S. presence. 

“This has been a year of transformation for Saniona, evolving from a company focused on early-stage research to one capable of conducting its own mid-stage clinical trials. As we close out 2020, the hiring of Denelle and Kyle completes Saniona’s executive team in support of our current business,” said Rami Levin, President and CEO of Saniona. “As we look to 2021, our entire organization is focused on initiating Phase 2b clinical trials of Tesomet in HO and PWS, as well as advancing SAN711, the first drug candidate from our library of more than 20,000 proprietary ion channel modulators, into the clinic.”

Denelle Waynick, Chief Legal Officer, has nearly 30 years of experience advising domestic and international companies in the healthcare and life sciences industries. Most recently, Waynick served as Chief Legal Officer and Corporate Secretary at MyoKardia, where she provided strategic and practical counsel to C-suite executives in legal matters, as well as issues impacted by the regulatory and policy environment. Waynick has also worked as in-house corporate counsel at UCB, Actavis and Schering-Plough, and in corporate law as an Associate and Partner at national and regional law firms. In addition to expertise in corporate, policy, governance and litigation matters, she has served as counsel on a range of global business transactions, including mergers, acquisitions and divestments. Waynick holds a B.S. in Accounting from Rutgers, the State University of New Jersey-Newark, and a JD from Howard University School of Law.

“Saniona is a company uniquely positioned for long-term success — with both a mid-stage product in clinical development and a robust research engine to further its pipeline. I am excited about joining the team and contributing to Saniona’s robust growth,” said Waynick.

Kyle Haraldsen, Chief Technical Operations Officer, has nearly 20 years of technical operations and manufacturing experience in the biopharmaceutical industry, including in support of U.S. and E.U. product approvals. Most recently, he served as the Vice President of Technical Operations and Project Management at AMAG Pharmaceuticals, where he led the process and analytical development, manufacturing, supply chain and project management functions. During his time at AMAG, Haraldsen oversaw multiple product launches, line extensions and the integration of two development stage assets. Prior to his time at AMAG, he was the Senior Director of Manufacturing at Radius Health, where he was responsible for the developmental, operational, and budgetary oversight of CMC programs and clinical trial material in support of global Phase 3 and multinational Phase 2 clinical trials. Haraldsen also worked for contract manufacturers Avecia Biotechnology and Johnson Matthey Pharma Services. He holds a B.S. in Chemical Engineering from Northeastern University.

“As Saniona prepares to execute significant clinical trial programs, it will be essential that we have a strong technical operations function to oversee the manufacturing and supply of product in line with clinical development activities and timelines. I am eager to ensure we have the people and processes in place to support successful execution of our clinical programs, and to begin planning pre-commercial manufacturing and supply chain strategy,” said Haraldsen.

Waynick and Haraldsen will serve on Saniona’s executive committee and will report to President and CEO Rami Levin. Both positions will be based in Saniona’s office in the Boston, Massachusetts-area, U.S. Waynick and Haraldsen will start in January 2021.

For more information, please contact

Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on December 21, 2020.

About Saniona

Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

 

Attachment

• Dec New Hires Press Release 12.21.20 (UK)

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
14-Dec-20	47,000	373.83	17,569,976.63
15-Dec-20	55,000	380.51	20,928,108.30
16-Dec-20	46,000	385.97	17,754,659.10
17-Dec-20	48,000	390.75	18,755,782.56
18-Dec-20	38,212	390.16	14,908,848.95

ASML’s current share buyback program was announced on 22 January 2020, and details are available on our website at https://www.asml.com/en/news/share-buyback

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

Media Relations Contacts	Investor Relations Contacts
Monique Mols, phone +31 6 528 444 18	Skip Miller, phone +1 480 235 0934
	Marcel Kemp, phone +31 40 268 6494

WALTHAM, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) — SeaChange International, Inc. (NASDAQ: SEAC), a leading provider of cloud based video delivery platforms worldwide, equips Content Providers and Owners with a cloud-based end to end OTT Streaming Platform, from Content Acquisition to Delivery, for Direct To Consumer (DTC) providers.

The SeaChange Framework offers best in class video back-office, asset management for automated content curation, metadata enrichment and quality control; user experience management with client applications for STBs, Smart-TVs and mobile devices; and a predictive analytics engine to increase viewer engagement and provide valuable targeting data for advertising. This SeaChange cloud solution enables rapid service launch with limited to no infrastructure investment, utilizing a cloud growth strategy that enables a pay as you go approach to scale.

Framework enables Targeted Dynamic Advertising in VOD and Linear OTT content, simplifying your Ad Sale operations: from creative inventory management, automated Ad Decision processing, full Demand/Buy Side integration with the Digital Marketplace, through the advertising revenue collection process, the SeaChange Framework handles it all.

“Many SeaChange Content Owner customers across the globe are using the Framework today to generate new advertising revenue streams through the automated sale of their ad inventory.” said Scott Apgar, VP Advanced Advertising. “Our unique solution which provides our partners with a full-service streaming platform, both Linear and VOD, by sharing in the revenue generated from offering ad inventory to Digital programmatic exchanges is groundbreaking.”

Contact:

Luiza Medeiros-Pinto
SeaChange International
978-606-6461
[email protected]

About SeaChange International

The Video Delivery Platform Leader.
SeaChange powers hundreds of cloud and on-premises platforms with Live TV and Video on Demand for over 50 million subscribers worldwide. SeaChange’s End-to-End solution, the Framework, includes all the necessary components to launch a direct-to-consumer service. This includes back-office, media asset management, ad management, analytics and a client application for STBs, Smart-TVs and mobile devices. The SeaChange solution is available as a product, SAAS and/or managed service, and can be deployed on-premises, in the cloud and as a hybrid. For more information, please visit www.seachange.com.

Safe Harbor Provision

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. Forward-looking statements can be identified by words such as “may,” “might,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “seeks,” “intends,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. Examples of forward-looking statements include, among others, statements we make regarding the ability of the enhanced Framework to identify users at risk of churning and for our customers to utilize such information to launch targeted retention actions, including the success of such actions; the overall ability of the Framework to reduce subscriber churn and increase customer revenues; the importance of understanding user behavior such as channel lineup utilization, VOD catalog engagement, and promotion effectiveness in improving the accuracy of advertising campaigns; the ability of Framework to leverage other products to provide scalable, cost-effective and compatible solutions and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of the Company and are subject to a number of known and unknown risks and significant business, economic and competitive uncertainties that could cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. Risks that could cause actual results to differ include, but are not limited to: the impact of COVID-19 on our business and the economies in which we operate; the level of acceptance of the enhanced Framework with our current and future customers; the successful deployment of the Framework’s new features; the continued spending by the Company’s customers on video solutions and services; the manner in which the multiscreen video and OTT markets develop; the Company’s ability to compete in the software marketplace; and other risks that are described in further detail in the Company’s reports filed from time to time with the Securities and Exchange Commission (SEC), which are available at www.sec.gov, including but not limited to, such information appearing under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K, as amended. Any forward-looking statements should be considered in light of those risk factors. The Company cautions readers that such forward-looking statements speak only as of the date they are made. The Company disclaims any intent or obligation to publicly update or revise any such forward-looking statements to reflect any change in Company expectations or future events, conditions or circumstances on which any such forward-looking statements may be based, or that may affect the likelihood that actual results may differ from those set forth in such forward-looking statements. 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a5baa4a5-4fcd-462a-9535-284857821891

SUGAR LAND, Texas, Dec. 21, 2020 (GLOBE NEWSWIRE) — CVR Energy, Inc. (NYSE: CVI) today announced that it has received full approval from the Company’s Board of Directors for its Wynnewood renewable diesel project, which will convert the refinery’s hydrocracker unit for renewable diesel service. Upon completion, which is expected in mid-2021, the Wynnewood refinery should have the capability to produce nearly 100 million gallons of renewable diesel per year and more than 6 million gallons of renewable naphtha per year, significantly reducing its annual Renewable Identification Number (“RIN”) exposure under the Clean Air Act’s Renewable Fuel Standard (“RFS”).

“We are pleased to report that our Board of Directors has granted final approval on Phase 1 of our renewable diesel strategy,” said Dave Lamp, CVR Energy’s Chief Executive Officer. “By leveraging assets already in place, particularly the existing hydrocracker unit and underutilized hydrogen plant at our Wynnewood refinery, we believe we can deliver one of the lowest cost renewable diesel projects in the industry.

“Detailed engineering design work for the project is underway,” Lamp said. “We also have ordered long lead-time equipment and began construction work, as authorized by the Oklahoma Department of Environmental Quality’s permitting rules. We continue to expect the unit to be in service by July 1, 2021.”

The Company currently estimates total capital costs for the project to be approximately $110 million, or $1.10 per gallon of renewable diesel capacity, most of which should be recouped by the end of 2022 through the generation of RINs as well as Blender’s Tax and Low Carbon Fuel Standard credits. The project is expected to produce more than 100 million gallons of renewable diesel and renewable naphtha per year, which would generate 170 million to 180 million RINs.

“Once completed, this project should further enhance our stated goal of reducing our reliance on RIN purchases to comply with the flawed RFS program,” Lamp concluded. “Between our existing blending capabilities and the RINs generated from renewable diesel, we expect our total net purchases would be less than 80 million RINs per year once the unit is up and running.”

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements concerning current estimates, expectations and projections about future results, performance, prospects, opportunities, plans, actions and events and other statements, concerns, or matters that are not historical facts are “forward-looking statements,” as that term is defined under the federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the renewable diesel project at the Wynnewood refinery including our ability to complete the project successfully or at all and the timing, cost, throughput, permitting, construction, production, in-service date, impact and benefit (if any) thereof; our renewable diesel strategy and phases thereof; RIN, Blenders’ Tax and Low Carbon Fuel Standard credits and our generation thereof; reduction of our reliance on RIN purchases; blending operations; our cost compared to other projects in the industry; and annual net RIN purchases. You can generally identify forward-looking statements by our use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. For additional discussion of risk factors which may affect our results, please see the risk factors and other disclosures included in our most recent Annual Report on Form 10-K, any subsequently filed Quarterly Reports on Form 10-Q and our other SEC filings. These and other risks may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof. CVR Energy disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

About CVR Energy, Inc.

Headquartered in Sugar Land, Texas, CVR Energy is a diversified holding company primarily engaged in the petroleum refining and marketing business through its interest in CVR Refining and the nitrogen fertilizer manufacturing business through its interest in CVR Partners, LP. CVR Energy subsidiaries serve as the general partner and own 35 percent of the common units of CVR Partners.

For further information, please contact:

Investor Relations:

Richard Roberts
CVR Energy, Inc.
(281) 207-3205
[email protected]

Media Relations:

Brandee Stephens
CVR Energy, Inc.
(281) 207-3516
[email protected]

SIMI VALLEY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) — Homepie, Inc^®, a provider of do-it-yourself tools for homebuyers and sellers who wish to transact without a real estate broker, announced their commitment to solving deceptive Realtor business practices. In the wake of the settlement between the Department of Justice and the National Association of REALTORS^® whereby Realtors^® admit to hiding buyer commissions, Homepie offers commission free real estate transactions.

Homepie is an innovative technological response to the market’s strong demand for a space that enables home buyers and sellers to connect directly with each other in real time with no commissions. This field of connecting buyers and sellers without a licensed real estate agent is called a peer to peer transaction, allowing parties to avoid real estate commissions like the 3% that is typically paid to the buyer’s agent by the home seller.

“Home sellers typically pay the listing agent a 6% commission which is then split with the buyer’s agent,” says Brad Rice, CEO of Homepie. The Department of Justice found that Realtors^® were not disclosing their homebuyer fees to their clients. Rice continues, “There is so much money being collected from the seller, that real estate companies are continually devising ways to divvy up the commission in an effort to ‘buy’ the business from their client with rebates, discounts, and more. This often goes largely undetected by the seller, who may not recognize that this money is coming out of their own pockets. I wanted to find a better solution.”

Homepie’s easy to use transaction wizard eliminates the Realtor^® and leverages technology to walk buyers and sellers through the transaction from start to finish with confidence, while representatives are always standing by to guide and assist with answering questions. Homepie provides all of the necessary documents, contracts, and disclosures so consumers don’t have to search for these on their own and they don’t charge any commissions. Additionally, their pool of preferred service providers can assist with optional closing services for mortgage, escrow, title, insurance, home inspections, and more.

In Los Angeles County, where the average home value is $535,000 according to housing data provider CoreLogic, keeping the 6% of a home’s value that would normally compensate real estate agents involved in the deal works out to about $32,000 in consumer savings. The Department of Justice wants Realtors^® to disclose the commissions paid.

Homepie’s website provides a safe, secure platform for guided negotiation of real estate sales online between a home buyer and seller. For those who would like to avoid the commission cost in a real estate transaction, they can manage contracts, provide the required legal disclosures, and all other paperwork needed for property transactions. The contract and negotiation tools are available for free to consumers on Homepie.com. Homepie receives advertising and fee revenue from lenders, inspectors, appraisers, transaction coordinators, escrow, insurance, and more. However, users of the Homepie platform are not obligated to use these partners.

With over 400 California homes currently active on the platform that homebuyers cannot access through a real estate agent, Homepie.com is quickly becoming a valued resource of properties that buyers may not be able to find anywhere else.

About Homepie

Homepie is the place where savvy consumers go for commission-free help to buy or sell homes. Today, nearly 1 in 10 home sales already close directly between buyer and seller without a real estate agent. Now, with Homepie’s central online marketplace and a simple step-by-step process, anyone can do the same with confidence. Homepie has all the tools to list, market, search, view, offer, negotiate, and auto-generate a purchase agreement that is digitally signed. Best of all, these tools are 100% free to consumers, as the recommended service providers (lenders, insurance, inspectors, etc.) cover the costs. Homepie takes the worry and guesswork out of home buying and selling. Learn how at homepie.com

Media Contact:


Jules Penham
801-971-8446
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3e1cdb42-752b-4fdd-b740-6c5c6aed384d

DAYTONA BEACH, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today it has acquired, through separate transactions, two single tenant properties net leased to Walgreens and Kohl’s for a combined purchase price of $15.4 million (the “Acquisitions”). The properties were purchased at a weighted average going-in cash cap rate of 7.1% and have a weighted average remaining initial lease term of approximately 9.3 years.

The Kohl’s, located in Glendale, Arizona, benefits from approximately 120,000 people in a 3-mile radius, average household incomes of approximately $89,000 and more than 45,000 vehicles per day along the West Bell Road retail corridor. The Walgreens is located in the Seattle submarket of Tacoma, Washington at an intersection that experiences almost 40,000 cars per day with similarly strong demographics. The properties are leased to, or the leases are guaranteed by the investment grade rated parent entities of Kohl’s or Walgreens, respectively.

In 2020, the Company has acquired 29 single tenant net leased properties for $116.6 million with a weighted average going-in cash cap rate of 6.9%, exceeding its previously provided acquisition guidance of $110 million. Including the new Acquisitions, the Company’s portfolio now consists of 48 properties located in 34 markets and 18 states across 18 industries, with a weighted average remaining lease term of 8.5 years.

About Alpine Income Property Trust, Inc.

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that acquires, owns and operates a portfolio of high-quality single tenant net leased properties.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.

Safe Harbor

This press release may contain “forward-looking statements.” Forward-looking statements include statements that may be identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company’s current expectations and assumptions regarding capital market conditions, the Company’s business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include general business and economic conditions, continued volatility and uncertainty in the credit markets and broader financial markets, risks inherent in the real estate business, including tenant defaults, potential liability relating to environmental matters, illiquidity of real estate investments and potential damages from natural disasters, the impact of the COVID-19 Pandemic on the Company’s business and the business of its tenants and the impact on the U.S. economy and market conditions generally, other factors affecting the Company’s business or the business of its tenants that are beyond the control of the Company or its tenants, and the factors set forth under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Contact:

Matthew M. Partridge Senior Vice President, Chief Financial Officer & Treasurer (386) 944-5643 [email protected]